Complete Cat Vaccination Schedule

Putting the timeline first because people searching this title need this table more than anything else. Everything that follows is explaining the basis behind every number and every choice in this table.

That is the skeleton. Now taking it apart.

Queens transfer IgG to kittens through colostrum. Note: colostrum, not regular milk. Approximately 24 hours after birth the intestinal epithelium loses its permeability, and after that point IgG in milk is no longer absorbed into circulation. So the entire passive immune protection a kitten will ever receive from its mother depends on how much colostrum it ingested in the first 24 hours of life and how high the IgG concentration in that colostrum was. Colostral IgG concentration depends on the queen's own antibody levels, and the queen's antibody levels depend on her vaccination history and natural infection history. A queen with a solid vaccination record will have high serum anti-FPV antibody titers, high colostral IgG concentrations, and her kittens will start with high MDA that takes longer to decline to levels that no longer interfere with vaccination. A stray queen that was never vaccinated and never naturally infected with FPV (relatively uncommon for FPV given its high prevalence, since most stray cats encounter FPV in kittenhood) may produce kittens whose MDA is already too low to protect or interfere by 6 weeks of age.

The half-life of MDA in cats is approximately 9 to 10 days. This figure comes from early serum kinetic studies; different publications report slightly different values (some report 8.4 days, others 10.4), but the order of magnitude is consistent. Extrapolating from this half-life, kittens with high initial titers may not see their MDA fall below the threshold for MLV vaccine interference until 16 weeks or even later. Kittens with low initial titers may reach that point by 8 weeks. Within the same litter, because individual kittens nurse different amounts of colostrum, initial MDA titers can also vary. Testing titers on every individual kitten to determine the optimal vaccination timepoint is the most precise approach in theory and completely impractical in routine clinical settings, both in cost and operational complexity.

So vaccine medicine adopted a pragmatic strategy: repeated vaccination to probabilistically cover this variable window. One shot at 6 weeks, one at 10 weeks, one at 16 weeks. At least one of those will land at a timepoint where MDA has dropped below the interference threshold. If a kitten's MDA drops into position by 8 weeks, then the first shot at 8 weeks is the effective one, and the subsequent two function as boosters. If another kitten's MDA is still interfering at 14 weeks, then the first two shots were both wasted, the 16-week shot is the first effective stimulation, and the one-year booster subsequently serves a function analogous to a "second dose." This is also why the one-year booster is so critical to the integrity of the immunization program.

The width of this window varies by individual. It can be as short as a few days or as long as two to three weeks. In high-density cat environments (shelters, catteries, cat cafes), the existence of this window means that even with strict adherence to a vaccination schedule, a certain proportion of kittens will be unprotected for some period of time. The UC Davis Koret Shelter Medicine Program's shelter operational guidelines (publicly available at sheltermedicine.com) therefore recommend shortening FVRCP vaccination intervals to every two weeks in shelter environments, while also administering intranasal FVRCP on the day of intake to establish mucosal local protection as quickly as possible. This aggressive two-week interval is neither needed nor recommended in household settings.

The FPV component's protection is very solid. Challenge trial data published by Schultz et al. in 2006 in Veterinary Microbiology (Vol.117, pp.75-79) showed DOI of at least 7.5 years for MLV FPV vaccine. Ronald Schultz himself (University of Wisconsin-Madison School of Veterinary Medicine, long-standing member of the WSAVA Vaccination Guidelines Group) has expressed at multiple veterinary continuing education events the view that MLV FPV vaccine may provide lifelong protection after a properly completed primary immunization series, and that the three-year booster interval is a conservative compromise rather than an immunological necessity. The FPV vaccine blocks both infection and shedding; a vaccinated cat exposed to FPV does not get sick, does not shed virus, does not transmit. The correlation between antibody titer and protection is very strong; a positive FPV antibody titer can very reliably predict that the individual is protected.

The defining biological feature of alpha-herpesviruses is neuronal latency. After primary infection, FHV-1 undergoes retrograde axonal transport to the trigeminal ganglion, where it establishes latency in neuronal nuclei as circular episomal DNA. In the latent state, the virus does not express a complete set of viral proteins (only minimal amounts of latency-associated transcripts, LAT), and the host immune system essentially cannot "see" the latent virus. Immune surveillance can only act when the virus reactivates, begins expressing lytic cycle proteins, and produces new viral particles, at which point the virus is already replicating and shedding at mucosal surfaces. This latency-reactivation cycle cannot be interrupted by any vaccine. Not because current FHV-1 vaccines fail to do it, but because vaccination as an immunological intervention is fundamentally incapable of reaching virus that has already established itself inside neurons.

The history of feline injection-site sarcoma needs to start from 1985. That year Pennsylvania passed a law mandating rabies vaccination for cats using inactivated vaccine (before that, cats in the state were not required to have rabies vaccination). During the same period, the first generation of adjuvanted FeLV vaccines entered the market and rapidly achieved widespread adoption across the United States. By 1991, Hendrick and Goldschmidt at the University of Pennsylvania published a brief report in Veterinary Pathology (Vol.28, pp.439-441) describing a statistically significant increase in fibrosarcoma cases they had observed in the interscapular region of cats, with foreign body particles consistent with vaccine adjuvant detected in the tissue surrounding the tumors. That report set off a chain reaction that continues to this day and fundamentally changed feline vaccination practice.

In 1996, the AAFP, AVMA, AHA, and VCS jointly established the Vaccine-Associated Feline Sarcoma Task Force (VAFSTF) to study the issue and develop response strategies.

The mechanism of adjuvants (aluminum salts being the most commonly used) at the injection site is to create a persistent antigen depot, extending the duration of immune stimulation through slow release of antigen, while the local inflammatory response triggered by the adjuvant itself recruits large numbers of immune cells to the injection site. In the vast majority of cats, this inflammatory response manifests as a self-limiting subcutaneous nodule that resolves within weeks to months. In a very small number of cats with genetic susceptibility, fibroblasts within this chronic inflammatory microenvironment undergo malignant transformation. p53 mutations and PDGF signaling pathway abnormalities have been detected in FISS tumor tissue, suggesting the transformation process involves classic tumor suppressor gene inactivation and sustained activation of proliferative signaling pathways.

Incidence data reported across different studies vary considerably (0.5 to 1 per 10,000 injections, with some long follow-up studies reporting higher figures), depending on study design, follow-up duration, and diagnostic criteria for FISS. This number looks very low at the individual level. At the population level, with hundreds of millions of cat vaccinations administered globally each year, even one in ten thousand translates to a substantial number of FISS cases annually.

If the same tumor occurs on the distal limb, amputation can achieve clean surgical margins in a single procedure, with a much higher cure rate. Feline quality of life after amputation is well-documented in the literature as maintainable at a good level.

This recommendation has existed since the late 1990s. In the 2020s, a considerable number of clinics still vaccinate cats in the interscapular region. The time required to change an entrenched clinical practice habit far exceeds the pace at which literature is published. The AAFP 2020 guidelines included distal limb vaccination as an explicit recommendation in the body text (page 821 of the guidelines), not a footnote, not an optional suggestion.

This is where the thread left open earlier when discussing kitten vaccine selection connects back. MLV core vaccines do not contain adjuvant. This is the second dimension, beyond MDA breakthrough capability, in which MLV is superior to inactivated adjuvanted vaccines. For non-core vaccines, Boehringer Ingelheim's PureVax product line offers non-adjuvanted recombinant rabies and FeLV vaccines using a canarypox virus vector. Canarypox virus can initiate but cannot complete a full replication cycle in mammalian cells (replication-defective), so it can express the inserted target antigen gene to stimulate an immune response without causing infection, and because it contains no aluminum salt adjuvant, the inflammatory response at the injection site is significantly reduced compared to adjuvanted inactivated products. In the context of FISS risk, non-adjuvanted products are preferred over adjuvanted products, and this priority is not disputed. Asking the veterinarian what product they are using is something cat owners should do.

Cats appear to have some species-specific predisposition toward malignant transformation in response to chronic inflammation from subcutaneous injections. Beyond vaccines, long-acting cephalosporin injections (cefovecin), sustained-release methylprednisolone injections, and even microchip implantation sites all have rare case reports of injection-site sarcoma. Dogs receiving the same injections almost never develop this problem. Feline fibroblast proliferative responses to chronic inflammatory stimuli may differ from those in other species; the specific molecular mechanisms are still under investigation with no definitive conclusions, though a small number of in vitro studies suggest that feline fibroblasts exposed to inflammatory mediators show higher proliferation rates and survival rates compared to canine fibroblasts. The operational conclusion is straightforward: reducing unnecessary subcutaneous injections in cats and choosing products with lower inflammatory responses, whenever there is a choice, carries greater safety weight in cats than in dogs.

On core vaccine product selection: MLV over inactivated adjuvanted vaccine. Two lines of evidence, both already covered above. Stronger MDA breakthrough capability is the first. No adjuvant, lower FISS risk is the second. If a clinic is using an inactivated adjuvanted product for core vaccination rather than MLV, the cat owner can request a switch.

On the three-year booster interval. Immunological evidence points to core vaccine DOI far exceeding three years after completion of a proper primary immunization series. The three-year interval is already a conservative compromise position. Annual core vaccination provides no additional immunological benefit.

At the execution level, a large number of clinics continue to administer core vaccines to cats annually, without explaining the frequency options, without informing clients that three-year intervals are the current guideline recommendation. Cat owners are told "it's time" and bring the cat in. A habit worth developing for cat owners: check the date of the last core vaccine. If it has not been three years, visiting the clinic for a wellness exam is sufficient, no core vaccine needed.

The situation for FCV is similar to FHV-1; the correspondence between antibodies and protection is not tight enough, compounded by the incomplete cross-protection issue caused by FCV genotypic diversity, making titer testing of limited value as well.

Since the three are a combined vaccine, a positive FPV titer result can only tell you that the cat is protected against panleukopenia. It says nothing about FHV-1 or FCV protection status. Given that FHV-1 and FCV vaccines do not provide infection-blocking level protection to begin with, the marginal benefit of increasing vaccination frequency for those two components is also limited.

FIV-positive cats. No MLV. Immunocompromised individuals receiving attenuated live virus carry the risk of reversion to virulence or abnormal viral replication. Use inactivated vaccines instead. Vaccination protocols for FIV-positive cats require case-by-case assessment depending on the clinical stage of FIV infection and exposure risk. The AAFP 2020 guidelines use very cautious language on this topic, acknowledging that evidence-based data are extremely limited.

FeLV vaccine. All kittens vaccinated. Adult indoor-only cats may discontinue boosters. The definition of "indoor-only" requires honesty: escaped through an unsecured window once, boarded at a friend's house, a new cat introduced whose FeLV status was not confirmed, none of these qualify as indoor-only. Progressive FeLV infection has no cure, and the prognosis is poor. Test with ELISA snap test to confirm FeLV status before vaccination (AAFP 2020 guidelines page 819, Table 1 footnote). Vaccinating a cat that is already progressively infected with FeLV has no therapeutic value. FeLV infection outcomes divide into three categories: abortive infection (virus cleared), regressive infection (viral genome integrates into host DNA but is suppressed, antigenemia resolves, can reactivate under severe immunosuppression), and progressive infection (persistent antigenemia, median survival no more than three years). Only progressively infected cats continuously shed virus and infect others. Regressively infected cats do not shed under normal immune conditions but can reactivate and convert to progressive infection under immunosuppression (concurrent FIV infection, chronic corticosteroid use, chemotherapy, for example).

This is placed later because the MDA section above already touched on its function: "if a kitten's MDA only drops into position at 14 weeks, the 16-week shot is the first effective stimulation, and the one-year booster serves a function analogous to a second dose." Following that logic further: the immunological function of the one-year booster is to convert the short-lived effector cell populations generated during primary immunization (mainly short-lived plasma cells) into long-lived plasma cells and memory B cells. Long-lived plasma cells reside in bone marrow and continuously secrete low levels of antibody to maintain serum titers without requiring antigen re-stimulation. Memory B cells, upon encountering antigen re-stimulation, rapidly differentiate into plasma cells producing large quantities of antibody (anamnestic response). The establishment of these two cell populations is the material foundation for immune protection persisting over subsequent years.